GlassScriptPhysician profile
Jocelyn Bush
NPI 1447356704
$20,124.76
in general payments reported to CMS, 2019-2025
47 companies · $2,536 in 2025
The $2,536 reported for 2025 was more than what 82% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,916 · 2020: $1,784 · 2021: $3,679 · 2022: $2,274 · 2023: $2,045 · 2024: $2,892 · 2025: $2,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,896 · Travel and Lodging: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,896.39 |
| Travel and Lodging | $576.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,126.12 | 2020-2025 | Wavewriter Alpha Prime 16, Intracept, Clinical Trial Product |
| Vertiflex, INC. | $2,127.49 | 2019 | |
| Abbvie INC. | $1,643.92 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Si-Bone, INC. | $1,483.97 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $1,213.78 | 2021 | |
| Collegium Pharmaceutical, INC. | $1,194.20 | 2019-2025 | Xtampza, Belbuca |
| Abbott Laboratories | $1,180.02 | 2019-2022 | |
| Vertos Medical, INC. | $1,120.82 | 2021-2024 | Mild Device Kit |
| Medtronic, INC. | $1,061.16 | 2021-2024 | Synchromedii, Vanta Adaptivestim |
| Spinefrontier, INC. | $812.41 | 2020 | |
| Mml US, INC. | $761.09 | 2023-2025 | Reactiv8 |
| Relievant Medsystems, INC. | $530.53 | 2021-2023 | Intracept |
| Tersera Therapeutics LLC | $419.45 | 2019-2025 | Prialt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $416.67 | 2019-2025 | Relistor |
| Stryker Corporation | $275.35 | 2024-2025 | Mild Device Kit |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $267.70 | 2019-2022 | |
| Amgen INC. | $212.83 | 2019-2022 | |
| Biotronik Nro, INC. | $193.67 | 2024-2025 | Prospera |
| Scilex Pharmaceuticals INC. | $193.56 | 2019-2025 | Ztlido |
| Almatica Pharma LLC | $178.47 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $161.64 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Mdd US Operations, LLC | $148.13 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $132.66 | 2019-2020 | |
| Lilly USA, LLC | $127.54 | 2021-2023 | Emgality, Reyvow |
| Nevro Corp. | $120.58 | 2019-2020 | |
| Spr Therapeutics, INC | $115.55 | 2021-2025 | Sprint Pns System |
| Arbor Pharmaceuticals, INC. | $112.67 | 2020-2021 | |
| Lundbeck LLC | $102.73 | 2024-2025 | Vyepti |
| Pacira Therapeutics, INC. | $95.33 | 2019-2021 | |
| Redhill Biopharma INC. | $92.95 | 2020-2021 | |
| Azurity Pharmaceuticals, INC. | $76.12 | 2024-2025 | Horizant |
| Impel Pharmaceuticals INC. | $71.59 | 2022-2023 | Trudhesa |
| Pfizer INC. | $49.27 | 2019-2020 | |
| Grt US Holding, INC. | $46.40 | 2021 | |
| Supernus Pharmaceuticals, INC. | $43.89 | 2021-2022 | |
| Bioventus LLC | $34.63 | 2022 | |
| Ossur Americas, INC. | $25.56 | 2024 | Miami J |
| Ibsa Pharma INC. | $20.54 | 2022 | |
| Virtus Pharmaceuticals LLC | $19.15 | 2021 | |
| Spinal Simplicity, LLC | $17.33 | 2024 | Ha Minuteman G3-R |
| Depuy Synthes Sales INC. | $15.98 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.97 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.17 | 2023 | Quviviq |
| Currax Pharmaceuticals LLC | $13.81 | 2022 | |
| Orexo US, INC. | $13.50 | 2025 | Zubsolv |
| Eisai INC. | $11.88 | 2021 | |
| Biodelivery Sciences International, INC. | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jocelyn Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.